NEW! TARGATT hypoimmunogenic hiPSC knock-in kit—learn more >

Contact Us
Contact Us
Brightfield microscope image of ASE-9550

ActiCells™ RUO Hypo hiPSCs

SKU ASE-9550 Categories , , ,

ActiCells™ RUO Hypo hiPSCs

Accelerate your allogeneic development by starting with a hypoimmunogenic iPSC platform reprogrammed from CD34+ cord blood cells. 

  • Hypoimmunogenic—B2M/CIITA double knock-out eliminates expression of HLA Class I and II molecules to avoid recognition by CD8+ and CD4+ T cells   
  • Favorable development profile—reprogrammed from CD34+ cord blood cells for reduced immunogenicity and fewer somatic mutations compared to reprogrammed adult cells 
  • Excellent differentiation potential—we’ve successfully differentiated the parental line into a number of cell types, including cardiomyocytes, NK cells, T cells, monocytes/macrophages, and endothelial cells 
  • Commercialization-ready—genome editing performed with Mad7 and TARGATT™ technology for a single, cost-effective license and clear freedom to operate
  • Genome editing ready—suitable for cell line engineering in our labs our yours 
Request more information

Overview

ActiCells™ RUO Hypo hiPSCs are research-use-only human induced pluripotent stem cells (hiPSCs) engineered to support the development of next-generation allogeneic cell-based medicines. Derived from CD34+ cord blood cells—a neonatal source known for its low mutational burden and reduced immunogenicity—these hiPSCs have been gene-edited to knock out both the β2 microglobulin (B2M) and HLA class II transactivator (CIITA) genes, further minimizing immune recognition through disruption of cell surface expression of MHC class I and II molecules.

The double B2M/CIITA knock-out makes ActiCells™ RUO Hypo hiPSCs an ideal foundation for building hypoimmunogenic, off-the-shelf therapeutic products. The cell line is ready for additional engineering, including the introduction of transgenes that further enhance immune evasion or deliver therapeutic effects. Whether you are designing universal donor cells or testing immune cloaking strategies, these hiPSCs offer a stable and flexible platform for allogeneic development.

Learn about how we can further engineer ActiCells™ RUO Hypo hiPSCs for your project through our iPSC gene editing services.

The ActiCells™ RUO Hypo hiPSCs will be the research-matching isogenic cell line to the ActiCells™ GMP Hypo hiPSCs which are in development.

Need to insert genes into your hypoimmunogenic iPSCs and want to do it in your own labs? We offer the  ActiCells™ RUO TARGATT™ Hypo hiPSC Knock-in Kit (Cat.# AST-9650) for efficient integration of your therapeutic payload into the H11 safe harbor locus.

Each vial of ActiCells™ RUO Hypo hiPSCs contains 1 x 106 cells. Every lot is tested for viability following recovery from cryopreservation, functional pluripotency (formation of the three germ layers), expression of pluripotency markers (OCT4, SOX2, NANOG, SSEA-4, and TRA-1-60), presence of alkaline phosphatase (AP), STR, sterility, and for the absence of mycoplasma and pathogens (CofA available upon request).
Table Header Table Header
Cat. #
ASE-9550
Reprogramming method
Episomal
Donor tissue
CD34+ Umbilical Cord Blood Cells
Gender
Male
Clinical information
Normal
Quantity
1 x 106 cells/vial
Request more information

How it works

Cell therapy rejection is, in part, mediated by CD8+ T cells (cytotoxic T cells), which interact with HLA class I molecules, and CD4+
T cells (helper T cells), which interact with HLA class II molecules (Figure 1).

Figure 1. Avoiding the host T cell response is critical for overcoming allograft rejection.

To make hypoimmunogenic hiPSCs, we eliminated cell surface expression of HLA I and HLA II molecules by knocking out two genes (Figure 2):

  • B2M, which encodes the ß2-microglobulin protein, a key part of the HLA class I complex
  • CIITA, the HLA II transactivator which is essential for transcription of HLA class II genes
Figure 2. Knocking out cell surface expression of HLA I and HLA II eliminates the T cell response, although other gene edits are needed to avoid innate immune responses. To eliminate cell surface expression of HLA I and HLA II we created a homozygous double knock-out of the B2M and CIITA genes in a hiPSC line.

Learn more about our approach to developing hypoimmunogenic hiPSCs by watching our webinar, “The Future of Allogeneic Therapy: ASC’s Hypoimmunogenic Donor Cells.” 

Request more information

Supporting data

Ready to learn more?

Fill out the contact form below and a team member will be in touch within one business day.

Contact form